Literature DB >> 20087944

Characterization of JC human polyomavirus infection in a Portuguese population.

Ana Matos1, Vitor Duque, Sílvia Beato, João Poiares da Silva, Eugene Major, António Meliço-Silvestre.   

Abstract

JC virus (JCV) is ubiquitous in the human population, infecting children asymptomatically. After primary infection, JCV persists in the host throughout life and is often excreted in the urine. Two hundred thirty-four urine samples and 78 serum samples, collected from 171 healthy individuals and 63 patients infected with HIV, were used to characterize JCV infection in a Portuguese population. Using PCR, JCV DNA was detected in 38% of the urine samples. A significant difference in the excretion rate was observed between patients infected with HIV (51%) and healthy individuals (33%). The frequency of JCV viruria increased with age in healthy individuals, but not in patients infected with HIV. JCV urinary load was determined by real-time quantitative PCR and was independent of gender, age, HIV infection, and CD4+ cell count. Overall, the JCV genotype detected most commonly was 1B, followed by genotypes 2B and 4. The detection and quantitation of JCV-specific antibodies were performed in serum samples by an established enzyme immunoassay (EIA). Antibodies to JCV were observed in 91% of the patients tested, irrespective of HIV infection. A positive correlation between JCV urinary load and antibody titers was demonstrated. The present study provides the first characterization of seroprevalence and urinary excretion of JCV in a Portuguese population and revealed similar results to those observed in other European countries. A comparison between healthy individuals and patients infected with HIV, despite identical values of seroprevalence, showed some differences in the pattern of urinary excretion. J. Med. Virol. 82:494-504, 2010. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20087944     DOI: 10.1002/jmv.21710

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  18 in total

1.  [Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology].

Authors:  C Warnke; O Adams; H P Hartung; R Gold; B Hemmer; R Hohlfeld; M Stangel; F Zipp; H Wiendl; B C Kieseier
Journal:  Nervenarzt       Date:  2011-10       Impact factor: 1.214

2.  A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.

Authors:  Salim Chahin; Joseph R Berger
Journal:  J Neurovirol       Date:  2014-11-18       Impact factor: 2.643

Review 3.  Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps.

Authors:  Fariha Zaheer; Joseph R Berger
Journal:  Ther Adv Drug Saf       Date:  2012-10

Review 4.  Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.

Authors:  Eric M L Williamson; Joseph R Berger
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 5.  Persistence and pathogenesis of the neurotropic polyomavirus JC.

Authors:  Hassen S Wollebo; Martyn K White; Jennifer Gordon; Joseph R Berger; Kamel Khalili
Journal:  Ann Neurol       Date:  2015-03-06       Impact factor: 10.422

6.  The changing landscape of progressive multifocal leukoencephalopathy.

Authors:  Sachin Kedar; Joseph R Berger
Journal:  Curr Infect Dis Rep       Date:  2011-08       Impact factor: 3.725

7.  Specific and quantitative detection of Human polyomaviruses BKPyV and JCPyV in the healthy Pakistani population.

Authors:  Iqra Hussain; Fareeda Tasneem; Muhammed Umer; Ayesha Pervaiz; Muslim Raza; Muhammad Imran Arshad; Naveed Shahzad
Journal:  Virol J       Date:  2017-04-24       Impact factor: 4.099

8.  JC virus antibody status underestimates infection rates.

Authors:  Joseph R Berger; Sidney A Houff; Julie Gurwell; Nubia Vega; Craig S Miller; Robert J Danaher
Journal:  Ann Neurol       Date:  2013-08-06       Impact factor: 10.422

9.  Analysis of variability of urinary excreted JC virus strains in patients infected with HIV and healthy donors.

Authors:  Danijela Karalic; Ivana Lazarevic; Ana Banko; Maja Cupic; Djordje Jevtovic; Tanja Jovanovic
Journal:  J Neurovirol       Date:  2017-12-14       Impact factor: 2.643

Review 10.  Progressive multifocal leukoencephalopathy: current treatment options and future perspectives.

Authors:  Dejan Pavlovic; Andriani C Patera; Fredrik Nyberg; Marianne Gerber; Maggie Liu
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.